Skip to content

Study · Animal study (in vivo) · mouse · 2025

8 results

Histochemical assessment of the anabolic effects of abaloparatide on the femoral metaphyses of ovariectomized mice.

Liu X, Hasegawa T, Sakakibara M, Yamamoto T, Haraguchi-Kitakamae M, Ishizu H, Shi Y, Cui J, Li W, Haoyu W, Hongo H, Shimizu T, Ohiro Y, Amizuka N

Journal of oral biosciences18 Apr 2025

PMID40254128 (opens in a new tab)DOI10.1016/j.job.2025.100663 (opens in a new tab)PepBankPUB-40254128
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, abaloparatide maintained trabecular number while it declined with vehicle.

    In plain wordsIn mice, abaloparatide maintained trabecular number while it declined with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseTrabecular number
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In the OVX group, trabecular number and bone volume gradually decreased over time, whereas the OVX + ABL group maintained these values to 6 weeks after OVX.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, abaloparatide maintained bone volume while it declined with vehicle.

    In plain wordsIn mice, abaloparatide maintained bone volume while it declined with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone volume
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In the OVX group, trabecular number and bone volume gradually decreased over time, whereas the OVX + ABL group maintained these values to 6 weeks after OVX.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, osteoclast numbers were similar between abaloparatide and vehicle except for a temporary increase with vehicle at 4 weeks.

    In plain wordsIn mice, osteoclast numbers were similar with abaloparatide and vehicle, except for a temporary vehicle increase at 4 weeks.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    MixedOsteoclast number per bone surface
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The numbers of TRAP-positive/cathepsin K-reactive osteoclasts per bone surface area were similar between the OVX and OVX + ABL group, except for a temporary increase at 4 weeks in the OVX group.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, ALP-positive cells surrounded trabeculae with abaloparatide while their areas decreased with vehicle.

    In plain wordsIn mice, bone-forming cells surrounded trabeculae with abaloparatide while their areas decreased with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseALP-positive osteoblastic cells
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In the OVX group, the areas of ALP-positive osteoblastic cells and PHOSPHO1-reactive mature osteoblasts decreased, whereas in the OVX + ABL group, ALP-positive osteoblastic cells surrounded the trabeculae, and long lines of PHOSPHO1-reactive mature osteoblasts expanded to the terminal region of the trabeculae.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, abaloparatide expanded mature osteoblast lines to terminal trabecular regions while their areas decreased with vehicle.

    In plain wordsIn mice, abaloparatide expanded mature bone-forming cell lines while their areas decreased with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreasePHOSPHO1-reactive mature osteoblasts
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In the OVX group, the areas of ALP-positive osteoblastic cells and PHOSPHO1-reactive mature osteoblasts decreased, whereas in the OVX + ABL group, ALP-positive osteoblastic cells surrounded the trabeculae, and long lines of PHOSPHO1-reactive mature osteoblasts expanded to the terminal region of the trabeculae.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice given abaloparatide, continuous calcein labeling on new bone indicated modeling-based bone formation.

    In plain wordsIn mice given abaloparatide, continuous bone labeling indicated new bone formation through modeling.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableModeling-based bone formation
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In addition, long continuous calcein labeling was seen on slightly convex new bone, indicating modeling-based bone formation in the OVX + ABL group.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, abaloparatide increased the bone formation rate per bone surface versus vehicle.

    In plain wordsIn mice, abaloparatide increased the bone formation rate per bone surface compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseBone formation rate per bone surface
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The bone formation rate/bone surface ratio and the total length of modeling-based bone formation sites were higher in the OVX + ABL group than in the OVX group.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized mice, abaloparatide increased total modeling-based bone formation site length versus vehicle.

    In plain wordsIn mice, abaloparatide increased the total length of modeling-based bone formation sites compared with vehicle.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseLength of modeling-based bone formation sites
    Study

    mousen: not reported in source

    ovariectomized female C57BL/6J mice
    Comparator
    vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg/day · intraperitoneal · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The bone formation rate/bone surface ratio and the total length of modeling-based bone formation sites were higher in the OVX + ABL group than in the OVX group.
    2 context sentences
    Summary · context
    Twelve-week-old female C57BL/6J mice underwent ovariectomies (OVX), and were then administered either abaloparatide (30 μg/kg/day: OVX + ABL group) or vehicle (OVX group) via daily intraperitoneal injection.
    Summary · context
    Femora were harvested at 0, 2, 4, and 6 weeks post-administration and subjected to micro-CT imaging, TRAP, cathepsin K, ALP, and PHOSPHO1 staining, along with calcein labeling.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.